Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026
January 10, 2025 06:30 ET
|
Dyne Therapeutics, Inc.
- DYNE-101 in DM1: Dyne plans to initiate global Registrational Expansion Cohort of ACHIEVE trial with registrational dose of 6.8 mg/kg Q8W following study data showing splicing correction and robust...
Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz
January 10, 2025 06:30 ET
|
Intra-Cellular Therapies, Inc.
BEDMINSTER, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics...
PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi Sequencing
January 10, 2025 06:05 ET
|
PacBio
MENLO PARK, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and...
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
January 10, 2025 06:02 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer
January 10, 2025 06:00 ET
|
Mersana Therapeutics, Inc.
- Emiltatug ledadotin observed to be generally well tolerated with differentiated safety and tolerability profile- Promising clinical activity observed in patients with triple-negative breast cancer...
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)
January 10, 2025 06:00 ET
|
Biodesix, Inc.
LOUISVILLE, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its preliminary financial results for the fourth quarter...
Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA
January 10, 2025 02:00 ET
|
HOOKIPA Pharma Inc.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION....
Shoals Technologies Group Files Additional Patent Infringement Complaint Against Voltage, LLC with the ITC
January 09, 2025 23:47 ET
|
Shoals Technologies Group
Shoals Technologies Group, Inc., maintains commitment to protecting U.S. Solar Manufacturing, files additional patent infringement complaint with ITC.
Astera Labs Announces Conference Call to Review Fourth Quarter 2024 Financial Results
January 09, 2025 18:30 ET
|
ASTERA LABS, INC.
Astera Labs Announces Conference Call to Review Fourth Quarter 2024 Financial Results
Texas Capital Bancshares, Inc. Announces Date for Full Year and Q4 2024 Operating Results
January 09, 2025 18:00 ET
|
Texas Capital Bancshares, Inc.
DALLAS, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, today announced that it expects to issue financial results for the...